# 4D Molecular Therapeutics, Inc. (FDMT)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Price:** $8.72 (-5.53%)

> 4D Molecular Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for ophthalmology and pulmonology diseases. It utilizes its proprietary Therapeutic Vector Evolution platform to create customized adeno-associated virus vectors that enable targeted, durable delivery of therapeutic payloads to specific tissues. The company's lead product candidate, 4D-150, targets retinal vascular diseases such as wet age-related macular degeneration and diabetic macular edema through a single intravitreal injection providing multi-year anti-VEGF production. Additional clinical programs include 4D-710 for cystic fibrosis lung disease, 4D-310 for Fabry disease cardiomyopathy, 4D-125 for X-linked retinitis pigmentosa, and 4D-110 for choroideremia. Preclinical candidates encompass 4D-175 for geographic atrophy and 4D-725 for alpha-1 antitrypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. maintains collaborations with partners like Astellas Gene Therapies, Arbor Biotechnologies, uniQure biopharma, and Otsuka Pharmaceutical for development and commercialization in select regions. Founded in 2013 and headquartered in Emeryville, California, the company advances product candidates through Phase 1, 2, and 3 trials to address unmet needs in chronic conditions.

Financial data not yet available for this company.

Source: [CompaniesByCap](https://companiesbycap.com/company/FDMT)